(Q36410425)

14 August 2017

1 reference

title

Screening and risk stratification of patients with the metabolic syndrome and diabetes (English)

1 reference

14 August 2017

1 reference

Nathan D Wong

1

1 reference

14 August 2017

1 March 2006

1 reference

Expert Review of Cardiovascular Therapy

14 August 2017

1 reference

14 August 2017

4

1 reference

14 August 2017

181-190

1 reference

14 August 2017

2

1 reference

Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.

14 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

High prevalence of metabolic syndrome in Hong Kong Chinese--comparison of three diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Mortality over a period of 10 years in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Prediction of coronary events with electron beam computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

The metabolic syndrome, diabetes, and subclinicalatherosclerosis assessed by coronary calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Relation of the metabolic syndrome to calcified atherosclerotic plaque in the coronary arteries and aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Metabolic syndrome and diabetes are associated with an increased likelihood of inducible myocardial ischemia among patients with subclinical atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Metabolic syndrome and echocardiographic left ventricular mass in blacks - the atherosclerosis risk in communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Risk factor thresholds: their existence under scrutiny

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

Coronary Disease and Stroke in Patients with Large-Vessel Peripheral Arterial Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.2.181

21 January 2018

Identifiers

DOI

10.1586/14779072.4.2.181

1 reference

14 August 2017

1 reference

PubMed ID

16509814